Newspaper Publication of Unaudited Financial Results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Limited has informed BSE that it published its unaudited financial results for the quarter and half year ended September 30, 2025 (Q2/H1 FY26) in two newspapers — Active Times (English) and Mumbai Lakshadeep (Marathi) on November 8, 2025, as required under SEBI LODR Regulations. On a consolidated basis, total operating income surged to Rs 4,583.99 lakhs in H1 FY26 versus Rs 1,254.14 lakhs in H1 FY25 (roughly 3.6x year-on-year growth). Despite strong revenue, the company slipped into a consolidated loss after tax of Rs 117.62 lakhs in Q2 FY26 (vs profit of Rs 121.52 lakhs in Q1 FY26), though H1 FY26 net profit stood at Rs 70.37 lakhs versus just Rs 3.90 lakhs in H1 FY25. Standalone numbers showed a Q2 FY26 profit after tax of around Rs 237.51 lakhs with H1 FY26 net profit at Rs 158.64 lakhs. EPS for the half year stood at Rs 0.02.
Strong top-line growth signals business expansion, but the swing-back to a consolidated loss in Q2 FY26 may raise concerns about cost pressures or one-off items; investors should watch the full results and management commentary for clarity on margins.